Study Of RV-39 In Patients Who Also Have Asthma

• Status: Terminated
• Trial end date: 2008-07-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will last up to 9 weeks. Subjects will visit the clinic up to 14 times. Certain clinic visits will include a physical examination, lung function tests, inflammatory cell analysis from nasal secretions and/or sputum, and blood draws. Subjects will inhale an FDA approved virus through their nose which is known to cause the common cold. All study related medications and medical examinations will be provided at no cost to the subject. The drugs used in this study are approved for the age group under study.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: GlaxoSmithKline
• Treatments: Fluticasone; Fluticasone Propionate, Salmeterol Xinafoate Drug Combination; Salmeterol Xinafoate; Xhance

Criteria

Inclusion Criteria:

• Have asthma for at least 3 months prior to the study.

• Have been using an allowed pre-study asthma therapy for at least 3 months prior to study.

• Demonstrate airway hyperresponsiveness following inhalation of bronchoconstrictor.

• Have a positive allergic status antibody test.

Exclusion Criteria:

• Have a history of life-threatening asthma.

• Been hospitalized for asthma within the 24 months prior to the study.

• Have certain conditions that would make study participation unsafe.

• The study doctor will evaluate other inclusion and exclusion criteria.